RCS - Angle PLC - Novel findings using Parsortix

AngleAnnouncement

06/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250206:nRSF0929Wa&default-theme=true

RNS Number : 0929W  Angle PLC  06 February 2025

 For immediate release  6 February 2025

 

ANGLE plc ("the Company")

 

Novel findings USING the PARSORTIX SYSTEM DEMONSTRATE ROLE OF CTC:B CELL
CLUSTERs IN driving CANCER progression

 

Findings may enable the development of novel drugs to target B cell and CTC
cluster interactions to suppress cancer metastasis

 

This pivotal work is likely to stimulate further interest in the Parsortix
system to investigate metastasis and drive clinical trials

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is delighted to announce the publication of
novel research by Professor Dario Marchetti's team at the University of New
Mexico Comprehensive Cancer Center, United States. The study used the
Parsortix(®) system to investigate CTC and B cell(*) clusters in clinical and
pre-clinical models of melanoma brain metastasis, and their ability to target
additional organs during the spread of cancer ("metastasis of metastasis").

 

This pivotal work is likely to stimulate further interest in using the
Parsortix system to investigate the process of metastasis and drive clinical
trials to develop new drugs to suppress metastasis, powered by the Parsortix
system.

 

By employing a newly developed humanised mouse model, the Marchetti team
demonstrated that the aggregation of B cells with CTCs, in CTC clusters,
enables cancer cells to be masked from the immune system enhancing their
metastatic potential. This finding increases our understanding of cancer
progression and may allow for the development of new treatments to suppress
cancer metastasis.

 

Notably, in an additional experiment, the researchers found a significantly
higher number of CTC:B cell clusters in blood samples from early stage
clinical melanoma patients that later progressed to develop metastatic
disease, compared to patients with existing metastasis. They hypothesised that
these CTC:B cell clusters may enhance the metastatic process and amplify
treatment resistance to immunotherapies. This could be of profound clinical
importance in determining which patients have aggressive disease and in
assessing their likely response to immunotherapy.

 

A second major finding of the study was to show that a specific gene signature
within CTC clusters acts like a postcode to guide CTCs from the brain to the
liver, thereby forming secondary liver metastasis which is associated with
poor patient outcomes. The discovery of a melanoma brain-liver axis, and by
implication similar axes for other sites in the body, could have important
clinical consequences for treating metastatic melanoma and identifying novel
drug targets for treatment.

 

The Parsortix system played an instrumental role in this research,
demonstrating another pivotal discovery made possible by ANGLE's unique,
marker-independent system which enables the collection of live CTC clusters
for downstream analysis.

 

Professor Dario Marchetti, The University of New Mexico Comprehensive Cancer
Center, commented:

"We are delighted to publish these novel findings which provide further
insight into the metastatic cascade as culmination of tumour progression. The
clinical potential of understanding how and why CTC clusters co-opt B cells to
cause fatal metastasis is of unique relevance to patient care and may lead to
new treatment options. The study of CTC clustering with immune cells has
allowed the discovery of a 'postcode' that tells us which organ the metastasis
will target next. This is the first evidence that the direction of metastasis
from primary to secondary disease has been reported and could enable the
development of a novel class of compounds to target the metastatic spread of
cancer.

 

The unique features of the Parsortix system have enabled my team to undertake
pioneering research in this promising field. We consider the Parsortix system
to be the best and most suitable technology to capture and interrogate
homotypic and heterotypic CTC clusters, from patient blood samples and
preclinical models of cancer, and the most advanced technology capable of
harvesting large numbers of CTC clusters. We are excited to build on this
discovery and its importance for developing treatment strategies which can
predict, and/or prevent metastatic disease."

 

Chief Scientific Officer, Karen Miller, commented:

"We are delighted to see another CTC cluster-based discovery shedding light on
the metastatic cascade that was fundamentally made possible by the Parsortix
system. We share Professor Marchetti's excitement for this innovative and
impactful work and congratulate his team on these novel findings. Furthermore,
we are extremely proud to see the Parsortix system playing an instrumental
part in such pioneering discoveries in cancer research and the implications
for drug discovery. We anticipate that interest in the Parsortix system will
increase as commercial and academic research into the metastatic pathway
continues to build."

 

The peer-reviewed publication is published in the journal Cancer Research
Communications, a premiere journal of the American Association for Cancer
Research and available for review at
https://angleplc.com/resources/publications/
(https://angleplc.com/resources/publications/)

 

* a B-cell is a type of white blood cell and part of the patient's immune
system

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer. The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood. The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays. The end user
is responsible for the validation of any downstream assay. The standalone
device, as indicated, does not identify, enumerate or characterize CTCs and
cannot be used to make any diagnostic/prognostic claims for CTCs, including
monitoring indications or as an aid in any disease management and/or treatment
decisions.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAAASEFKSEAA